DASL-CRC: A Novel Approach to Identify Molecular Markers of Metastatic Recurrence
DASL-CRC:一种识别转移复发分子标志物的新方法
基本信息
- 批准号:7451177
- 负责人:
- 金额:$ 15.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant ChemotherapyAdverse eventAmericasArtsBiological AssayBiological MarkersBlindedCancer EtiologyCancer PatientCessation of lifeChemotherapy-Oncologic ProcedureClinicalClinical TrialsColonColon CarcinomaConsensusDataDeveloped CountriesDeveloping CountriesDiagnosisDiagnostic Neoplasm StagingDiagnostic testsDiseaseDistant MetastasisDoctor of PhilosophyEuropeFluorouracilFormalinGene Expression ProfileGenesGenetic TranscriptionGenus ColaGoalsIncidenceIndividualIsraelLeucovorinLocalizedLymph Node InvolvementMalignant NeoplasmsMalignant neoplasm of prostateMetastatic toMicellar Electrokinetic Capillary ChromatographyMolecular ProfilingMorbidity - disease rateMucous MembraneMuscleNeoplasm MetastasisNumbersOligonucleotidesOperative Surgical ProceduresOutcomeParaffin EmbeddingPathologicPatientsPrincipal InvestigatorProgression-Free SurvivalsPublic HealthRadiation therapyRectal CancerRecurrenceRecurrent Malignant NeoplasmRecurrent diseaseRelapseSolid NeoplasmSpecimenStage at DiagnosisStagingSubmucosaSurvival RateTechnologyTestingTimeTissuesTodayTranslatingTumor stageWritingbasechemotherapycost effectivedesignexperiencelymph nodesnovelnovel strategiesoutcome forecasttumor
项目摘要
DESCRIPTION (provided by applicant): For Stage II colon cancer patients, the benefits of chemotherapy do not clearly outweigh the associated morbidity from adverse events. The majority of patients with stage II disease in Europe and the Americas therefore do not receive adjuvant chemotherapy after surgery. Unfortunately, 25-30% of stage II colon cancer patients relapse and die from metastatic disease within 6 years. Our team has recently developed a sensitive, reproducible and cost effective assay technology (DASL) that can generate high quality RNA expression profiles from routinely collected formalin fixed paraffin embedded (FFPE) tissue specimens. Our team has also recently identified gene expression signatures associated with metastatic potential (in prostate cancer), has significant experience in the successful design and application of novel gene arrays, and has substantial numbers of FFPE specimens from Stage II colon cancer patients with well characterized metastatic recurrence, progression free survival and other clinical outcome data. We therefore propose: SPECIFIC AIM 1: To identify a gene expression signature that can predict which stage II colon cancer patients relapse and die from metastatic disease. We will profile metastasis genes in tumors from 120 stage II colon cancer patients with and without metastatic recurrence using a novel Illumina DASL oligonucleotide bead array (DASL- Colon Recurrent Cancer; DASL-CRC).
SPECIFIC AIM 2: To validate the DASL-CRC stage II colon cancer metastasis signature. We will test the hypothesis that the DASL-CRC signature generated in Aim 1 can correctly identify in a second, non-overlapping set of 120 tumors the stage II colon cancer patients who die from metastatic relapse. In summary, this project will use state of the art technology to discover and validate an FFPE gene expression profile that accurately predicts the subset of Stage II patients who are most likely to die from recurrent disease, and who therefore are most likely to benefit from adjuvant chemotherapy.
PUBLIC HEALTH RELEVANCE: For Stage II colon cancer patients, the benefits of chemotherapy do not clearly outweigh the associated morbidity from adverse events. This proposal seeks to identify a molecular signature of metastasis to help identify those patients who will benefit most from chemotherapy.
描述(由申请人提供):对于II期结肠癌患者,化疗的获益并未明显超过不良事件的相关发病率。因此,欧洲和美洲的大多数II期疾病患者在手术后不接受辅助化疗。不幸的是,25-30%的II期结肠癌患者在6年内复发并死于转移性疾病。我们的团队最近开发了一种灵敏、可重复且具有成本效益的检测技术(DASL),可以从常规收集的福尔马林固定石蜡包埋(FFPE)组织标本中生成高质量的RNA表达谱。我们的团队最近还确定了与转移潜能相关的基因表达特征(在前列腺癌中),在成功设计和应用新型基因阵列方面具有重要经验,并且具有大量来自II期结肠癌患者的FFPE标本,这些患者具有良好的转移复发特征,无进展生存期和其他临床结局数据。因此,我们提议:具体目标1:确定一个基因表达特征,可以预测哪些II期结肠癌患者复发并死于转移性疾病。我们将使用新型Illumina DASL寡核苷酸珠阵列(DASL-Colon Recurrent Cancer; DASL-CRC)分析来自120名具有和不具有转移性复发的II期结肠癌患者的肿瘤中的转移基因。
具体目的2:验证DASL-CRC II期结肠癌转移特征。我们将测试以下假设:目标1中生成的DASL-CRC签名可以在第二个非重叠的120个肿瘤组中正确识别死于转移性复发的II期结肠癌患者。总之,该项目将使用最先进的技术来发现和验证FFPE基因表达谱,该基因表达谱可准确预测最有可能死于复发性疾病的II期患者子集,因此最有可能从辅助化疗中获益。
公共卫生关系:对于II期结肠癌患者,化疗的益处并不明显超过不良事件的相关发病率。该提案旨在确定转移的分子特征,以帮助确定那些将从化疗中获益最多的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven M Lipkin其他文献
Kinetics of cancer: a method to test hypotheses of genetic causation
癌症动力学:检验遗传因果假设的方法
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:3.8
- 作者:
Steven A Frank;Peng;Steven M Lipkin - 通讯作者:
Steven M Lipkin
Steven M Lipkin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven M Lipkin', 18)}}的其他基金
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
- 批准号:
10307526 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
- 批准号:
10056203 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
Neoantigen Vaccination for Lynch Syndrome Immunoprevention
林奇综合征免疫预防的新抗原疫苗接种
- 批准号:
9789215 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
Neoantigen Vaccination for Lynch Syndrome Immunoprevention
林奇综合征免疫预防的新抗原疫苗接种
- 批准号:
10478171 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
阐明 MALAT1 体细胞驱动突变在结直肠癌中的作用
- 批准号:
10532219 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
(PQ1) 调节林奇综合征外显率的适应性免疫和微生物机制
- 批准号:
10229450 - 财政年份:2018
- 资助金额:
$ 15.9万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 15.9万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 15.9万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 15.9万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 15.9万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 15.9万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 15.9万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 15.9万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 15.9万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 15.9万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 15.9万 - 项目类别: